Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 7/20 | 0.35 |
| ▸ | CA2 | P00918 | 7/20 | 0.35 |
| ▸ | BCHE | P06276 | 5/20 | 0.35 |
| ▸ | ACHE | P22303 | 5/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003571 | 0.89 | KMT2A (0.40) | MEN1KMT2AHIF1ATSHR | |
| SCHEMBL13309981 | 0.87 | TGM2 (0.40) | MEN1KMT2AHIF1ABCHEACHE | |
| SCHEMBL14291194 | 0.86 | AKR1B1 (0.40) | MEN1KMT2ATSHR | |
| SCHEMBL3293230 | 0.83 | AKR1B1 (0.35) | MEN1KMT2ACA1CA2ACHE | |
| SCHEMBL7170464 | 0.83 | KMT2A (0.43) | MEN1KMT2AHIF1ACA1CA2 | |
| SCHEMBL2538468 | 0.83 | KMT2A (0.43) | MEN1KMT2AHIF1ACA1CA2 | |
| SCHEMBL13293957 | 0.80 | KCNH2 (0.40) | MEN1KMT2A | |
| SCHEMBL14291204 | 0.79 | AKR1B1 (0.35) | MEN1KMT2ATSHR | |
| SCHEMBL437799 | 0.77 | KMT2A (0.41) | MEN1KMT2AHIF1ACA1CA2 | |
| SCHEMBL443090 | 0.77 | KMT2A (0.41) | MEN1KMT2AHIF1ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334320-B2 | Methods for chelation therapy | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-20100310460-A1 | COMPOSITIONS AND METHODS FOR CHELATION THERAPY | LIU GANG | 2010-12-09 | — | — | US | disclosed |
| US-7728038-B2 | Methods for chelation therapy | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-20060030619-A1 | Compositions and methods for chelation therapy | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310460-A1 | COMPOSITIONS AND METHODS FOR CHELATION THERAPY | SOST, SOD3, HIF1AN | MEN1 2161/4885KMT2A 1252/4885HIF1A 17/4885 |
| US-20060030619-A1 | Compositions and methods for chelation therapy | SOST, SOD3, HIF1AN | MEN1 2161/4885KMT2A 1252/4885HIF1A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.